evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,822 questions · 1,891 findings · 321 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 279 · 14.8%GRADE not reported 46 · 2.4%Very low 524 · 27.7%Low 571 · 30.2%Moderate 330 · 17.5%High 141 · 7.5%

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with ultra low dose (<2 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with ultra low… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ When compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Mental state: No clinically important improvement · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in mental state: No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).

4 findings from 1 review
Show 1 more finding

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ dystonia ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Prophylactic corticosteroids vs placebo or no corticosteroids

Gastrointestinal bleeding · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass

Prophylactic corticosteroids showed no clear difference in gastrointestinal (GI) bleeding (as defined by study authors,… compared with placebo or no corticosteroids (low certainty).

1 finding from 1 review

Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system

Adverse effects during treatment ‐ heaviness in lower abdomen · endometrial hyperplasia

It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes adverse effects during treatment ‐ heaviness in lower abdomen compared with levonorgestrel intrauterine system (very low certainty).

1 finding from 1 review

Familiar odour (breast milk smell) vs usual care

Pain (PIPP) · neonates with mechanical ventilation

Familiar odour (breast milk smell) showed no clear difference in PIPP during endotracheal suctioning Range of scale 0 to 21. Lower… compared with standard care (low certainty).

1 finding from 1 review